ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Protective Effect of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on Liver Function: Results From MELD Analysis in Surgical Revascularization-A Preliminary Study.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Coronary artery disease is associated with long-term systemic inflammation and perioperative multiorgan vulnerability, including transient hepato-renal dysfunction after cardiac surgery. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide cardiorenal protection beyond glucose lowering via anti-inflammatory, metabolic, and endothelial effects, but their effect on perioperative liver-related risk markers, including the Model for End-Stage Liver Disease (MELD) score, in off-pump coronary artery bypass grafting (OPCAB) remains uncertain. MATERIAL AND METHODS We retrospectively studied 111 consecutive patients undergoing elective OPCAB in 2024 (chronic hepatic or renal disease excluded). Patients were stratified by long-term preoperative SGLT2i therapy (≥3 months): no SGLT2i (n = 85) vs SGLT2i (n = 26). MELD score, bilirubin, international normalized ratio , and creatinine were assessed preoperatively and on postoperative days 1 and 6. Between-group comparisons used the Mann-Whitney U test; within-group changes were analyzed using the Friedman test, Kendall's W, and Bonferroni post hoc testing RESULTS Baseline MELD and components were comparable. On postoperative day 1, SGLT2i group exhibited lower bilirubin (P < 0.001), INR (P = 0.04), and MELD score (P = 0.03), but higher creatinine (P = 0.002). By day 6, differences attenuated. Within-group analysis showed significant time effects for MELD, INR, and creatinine in both groups, with large effect sizes (W = 0.48-0.88). Total bilirubin changed over time in the control but not the SGLT2i group. CONCLUSIONS Long-term preoperative SGLT2i therapy was associated with distinct perioperative MELD dynamics in OPCAB, with relative preservation of bilirubin and INR despite creatinine changes, suggesting the potential modulation of hepatic function during perioperative stress. Given the observational design and possible confounding, results are hypothesis-generating and warrant prospective confirmation..
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.